Glutamate ionotropic receptor NMDA type subunit 1 (GluN1) glycine-binding site (GluN1 glycine site)

The Glutamate ionotropic receptor NMDA type subunit 1 (GluN1) contains the obligatory strychnine-insensitive glycine-binding site, which is essential for the activation of the N-methyl-D-aspartate (NMDA) receptor complex (UniProt: P17342). Unlike most ligand-gated channels that require a single neurotransmitter, the NMDA receptor is a heterotetramer that requires the simultaneous binding of glutamate to the GluN2 subunit and glycine or D-serine to the GluN1 subunit to transition to an open state (PubMed: 11520916). This site plays a pivotal role in modulating synaptic plasticity and long-term potentiation, which are the cellular substrates for learning and memory (StatPearls: NBK526134). In pathology, NMDA receptor hypofunction—often linked to insufficient glycine site occupancy—is a leading hypothesis for the pathophysiology of schizophrenia, particularly its cognitive and negative symptoms (PubMed: 25205046). Conversely, overactivation of the receptor can lead to calcium-mediated excitotoxicity, contributing to neuronal death in stroke and neurodegenerative diseases (PubMed: 12467378). Pharmacological strategies include using glycine site agonists or positive allosteric modulators like Rapastinel to enhance NMDA signaling in psychiatric disorders, or antagonists like Gavestinel to provide neuroprotection by preventing excessive ion influx (PubChem: CID 60956).

Other names

GRIN1NMDAR1Strychnine-insensitive glycine siteNMDA receptor subunit zeta-1GluRzeta1

The glycine-binding site on the GluN1 subunit serves as a mandatory co-agonist site; binding of glycine or D-serine is required concurrently with glutamate binding to the GluN2 subunit to allow the NMDA receptor's cation-conducting pore to open (PubMed: 11520916).